Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

NCT05383716 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Neoadjuvant Therapy
Immune Checkpoint Inhibitor

Interventions

DRUG: Pembrolizumab

Sponsor

Peking Union Medical College Hospital